港股異動 | 李氏大藥廠漲超17%,擬分拆兆科眼科於香港上市
uSMART盈立智投12月21日消息,週一港股,李氏大藥廠高開高走,截至10:18分,李氏大藥廠漲超17%。
李氏大藥廠旗下兆科眼科已於12月18日正式向港交所遞交招股說明書,擬主板掛牌上市,高盛與傑弗瑞擔任聯席保薦人。

今年7月9日,李氏大藥廠在港交所發佈公告稱,考慮分拆兆科眼科獨立上市。
兆科眼科是一間眼科製藥公司,致力於療法的發現、開發及商業化,以滿足中國國內巨大醫療需求缺口。已建立起包含23種候選藥物的全面眼科藥物管線,涵蓋影響眼前節及眼後節的多數主要眼科疾病及症狀。
爲準備近期的產品推出,亦已建立一座頂尖眼藥製造設施並正在組建一支經驗豐富的營銷團隊。
獲明星機構青睞
兆科眼科獲得了藍籌投資者(包括新加坡政府投資公司、高瓴資本、TPG、正心谷資本、奧博資本及愛爾眼科醫院)的大力支持。
中國眼科藥物市場前景廣闊
中國有大量未獲得充分治療的眼科患者人口。根據灼識的資料,2019年,中國眼睛疾病總患病率大幅高於美國,但中國的眼科藥物市場規模僅是美國的六分之一,表明中國市場存在巨大增長潛力。
根據灼識的資料,中國眼科藥物市場預計將由2019年的26億美元增至2030年的202億美元,複合年增長率爲20.6%。然而,由於缺乏專注於眼科學,具備領域特定專業知識,能夠爲本專科治療領域提供全面解決方案的行業領導者,該市場高度分化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.